IRIS
DI BIAGIO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 34.029
AS - Asia 4.923
NA - Nord America 3.280
SA - Sud America 402
AF - Africa 112
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 42.753
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 33.202
US - Stati Uniti d'America 3.065
SG - Singapore 1.916
CN - Cina 1.273
VN - Vietnam 866
BD - Bangladesh 367
FR - Francia 341
BR - Brasile 244
HK - Hong Kong 152
FI - Finlandia 127
CA - Canada 100
DE - Germania 90
MX - Messico 70
AR - Argentina 69
GB - Regno Unito 68
JP - Giappone 49
IN - India 44
IQ - Iraq 42
NL - Olanda 35
ID - Indonesia 33
ZA - Sudafrica 28
CH - Svizzera 25
PH - Filippine 24
PK - Pakistan 21
CL - Cile 20
TR - Turchia 20
EC - Ecuador 19
RU - Federazione Russa 16
VE - Venezuela 16
ES - Italia 15
IE - Irlanda 15
UA - Ucraina 15
MA - Marocco 14
SA - Arabia Saudita 14
TN - Tunisia 14
ET - Etiopia 13
TH - Thailandia 13
UZ - Uzbekistan 13
CO - Colombia 11
DZ - Algeria 10
JM - Giamaica 10
NP - Nepal 10
PY - Paraguay 10
PE - Perù 9
KE - Kenya 8
MY - Malesia 8
JO - Giordania 7
TW - Taiwan 7
PL - Polonia 6
SE - Svezia 6
AE - Emirati Arabi Uniti 5
AT - Austria 5
AU - Australia 5
BE - Belgio 5
DO - Repubblica Dominicana 5
EG - Egitto 5
LT - Lituania 5
MD - Moldavia 5
RS - Serbia 5
SY - Repubblica araba siriana 5
CR - Costa Rica 4
CZ - Repubblica Ceca 4
GT - Guatemala 4
KR - Corea 4
KZ - Kazakistan 4
PS - Palestinian Territory 4
RO - Romania 4
SN - Senegal 4
AZ - Azerbaigian 3
BH - Bahrain 3
BO - Bolivia 3
DK - Danimarca 3
GA - Gabon 3
GR - Grecia 3
HR - Croazia 3
HU - Ungheria 3
IL - Israele 3
LB - Libano 3
MT - Malta 3
NG - Nigeria 3
NO - Norvegia 3
SI - Slovenia 3
SV - El Salvador 3
AG - Antigua e Barbuda 2
BB - Barbados 2
BG - Bulgaria 2
BS - Bahamas 2
CU - Cuba 2
GH - Ghana 2
IR - Iran 2
KG - Kirghizistan 2
LV - Lettonia 2
MK - Macedonia 2
NI - Nicaragua 2
PA - Panama 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AL - Albania 1
AM - Armenia 1
Totale 42.729
Salva come PNG Salva come JPEG
Città #
Genova 16.241
Genoa 10.621
Rapallo 2.896
Vado Ligure 2.872
San Jose 870
Singapore 850
Ashburn 420
Lauterbourg 311
Ho Chi Minh City 254
Beijing 243
Hanoi 218
Council Bluffs 207
New York 184
Hong Kong 147
Helsinki 117
Bordighera 89
Santa Clara 70
Frankfurt am Main 68
Los Angeles 68
Haiphong 54
St Louis 52
Milan 47
Mexico City 44
Rome 42
Tokyo 42
Boardman 40
Chicago 36
Buffalo 32
Da Nang 32
Dallas 30
São Paulo 28
Tianjin 28
Orem 27
Atlanta 26
Biên Hòa 22
Toronto 22
Turin 22
Naples 19
Zurich 19
Baghdad 17
Montreal 17
City of London 16
Amsterdam 15
Dhaka 15
Dublin 15
Palermo 15
Rio de Janeiro 15
Florence 13
Hải Dương 13
Shanghai 13
Guangzhou 12
Houston 12
London 12
Philadelphia 12
Bari 11
Bologna 11
Brooklyn 11
Bắc Ninh 11
Phoenix 11
Des Moines 10
Jakarta 10
Johannesburg 10
Tashkent 10
Cardiff 9
Charlotte 9
Kyiv 9
Lappeenranta 9
Nuremberg 9
Paris 9
Santiago 9
Addis Ababa 8
Istanbul 8
Lima 8
Marseille 8
Ninh Bình 8
Shenzhen 8
Tunis 8
Amman 7
Asunción 7
Bergamo 7
Can Tho 7
Curitiba 7
Denver 7
Las Vegas 7
Miami 7
Quảng Ngãi 7
The Bronx 7
Thái Nguyên 7
Verona 7
Bắc Giang 6
Campinas 6
Cape Town 6
Caracas 6
Guayaquil 6
Jeddah 6
Kingston 6
Lahore 6
Madrid 6
Manchester 6
Nha Trang 6
Totale 37.986
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 330
CD8+CD28-CD127loCD39+regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection? 259
The Ligurian Human Immunodeficiency Virus Clinical Network: A Web Tool to Manage Patients With Human Immunodeficiency Virus in Primary Care and Multicenter Clinical Trials 244
Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc 237
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. 228
Inflammation markers correlate with common carotid intima-media thickness in patients perinatally infected with human immunodeficiency virus 1. 227
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study 225
Quality of Life Among Hiv Patients: Results from the Ianua Clinical Trial 224
Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: A multicenter regional simulation 223
A tool for the evaluation of the cost effectiveness of AIDS therapies 221
Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system 219
Trend of eGFR in an Italian cohort of mother-to-child HIV-infected patients exposed to tenofovir for at least 2 years. 218
Is it still worthwhile to perform quarterly CD4+ T lymphocyte cell counts on HIV-1 infected stable patients? 218
Bloodstream infections in patients living with HIV in the modern cART era 218
A Standard Interface for Data Reuse in Infectious Diseases 217
La vaccinazione nel paziente con infezione da HIV: attuali raccomandazioni e strategie multidisciplinari per il raggiungimento dei soggetti suscettibili. L’esperienza della Liguria 208
Budget Impact Analysis of Sofosbuvir-Based Regimens for The Treatment of Hiv/Hcv Co-Infected Patients In Northern Italy: The Liguria Region Simulation 207
'Emergency exit' of bone-marrow-resident CD34+ DNAM-1 bright CXCR4+-committed lymphoid precursors during chronic infection and inflammation 200
Quality of life in an Italian cohort of people living with HIV in the era of combined antiretroviral therapy (Evidence from I.A.N.U.A. Study-Investigation on Antiretroviral Therapy) 199
A comparison of inpatient admissions in 2012 from two European countries 197
Use of maraviroc in clinical practice: a multicenter observational study 193
Commentary: Human Immunodeficiency Virus and Allergic Bronchopulmonary Aspergillosis 193
Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy 193
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 192
Cost per care of the first year of direct antiviral agents in the liguria region: A multicenter analysis 191
Ricoveri ospedalieri dei pazienti con infezione da HIV in Liguria: risultati preliminari dello studio ACTEA 191
Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study 190
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 189
A prospective randomized trial on abacavir/ lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study) 186
Disseminated histoplasmosis with mucocutaneous immune reconstitution inflammatory syndrome in an HIV-infected patient 184
Rete Ligure dell’HIV: due anni di esperienza nella gestione del dato clinico 182
Inpatient admissions of patients living with HIV in two European centres (UK and Italy); comparisons and contrasts 179
Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. 178
Pharmacokinetics of Lopinavir Determined with an ELISA Test in Youths with Perinatally Acquired HIV. 178
Bloodstream infections in patients living with HIV infection in the recent cART era: did something change?”. 178
Chemotherapy Mass Campaigns and Migratory Flows: An Unexpected Connection 177
Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy 177
Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study 177
Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course 176
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 175
Bloodstream infections in critically ill patients with COVID-19 175
Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine reverse transcription inhibitor backbone 171
Bone quality in perinatally HIV-infected children: role of age, sex, growth, HIV infection, and antiretroviral therapy 169
Bedaquiline: A new hope for shorter and better anti-tuberculosis regimens 169
Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA < 50 cp/mL 169
Different evidence of key amprenavir resistance mutations on the efficacy of darunavir 167
Reducing CD4+ lymphocyte cell monitoring in HIV-1 stable patients: a forecast of the cost saving 167
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 167
Predictors of retention in care for HIV-infected patients: data from San Martino Hospital cohort in Genoa 166
Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy. 163
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 163
How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy 161
Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation. 160
External validation of unsupervised COVID-19 clinical phenotypes and their prognostic impact 158
Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children 158
Simplification to monotherapy with lopinavir/ritonavir in adolescents with vertically acquired HIV-1 infection. 158
Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy 158
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 157
The Use of Nucleoside Reverse Transcriptase Inhibitors Sparing Regimens in Treatment-Experienced HIV-1 Infected Patients. 156
Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort. 156
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients 156
Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1-Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort. 156
Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature 156
How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis 156
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 155
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 154
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA) 154
Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response 152
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 152
Clinically stable treatment-experienced adults receiving tenofovir and didanosine. 151
From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital Platform Improved Doctors' Work and Patients' Care 150
A comprehensive development agenda on tenofovir alafenamide in clinical practice 150
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 149
Control of the HIV-1 DNA reservoir is associated in vivo and in vitro with NKp46/NKp30 (CD335 CD337) inducibility and interferon gamma production by transcriptionally unique NK cells 149
Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome 149
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia 149
Correction to: Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy (Infection, 10.1007/s15010-017-1063-7) 148
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 147
IANUA: a regional project for the determination of costs in HIV-infected patients 147
Ibalizumab and fostemsavir in the management of heavily pre-treated HIV-infected patients 147
Architettura, Design e Visualità 146
Infectious Complications of Cancer Chemotherapy in HIV Patients 146
Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration 145
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 145
Efficacy and safety of darunavir and etravirine in an antiretroviral multiexperienced youth with vertically HIV-1 infection 145
Cost assessment of haart: the ianua clinical trial in Genoa 144
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 144
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy? 144
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity 144
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 143
Assessment of appropriateness of first-line combined antiretroviral treatment (cART): the preliminary results of Liguria experience V.E.L.A. study 143
Exophytic Lesion of the Tongue in a Patient with Undetectable HIV-RNA in the Past 3 Years 142
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 142
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 142
Ligurian Vaccination in HIV Program (LIV in HIV): the experience of Genoa metropolitan area 142
La conta dei linfociti nel monitoraggio del paziente con infezione da HIV: evidenze per un impiego ragionato 142
CD8+CD28-CD127loCD39+Treg Expansion: a New Pathogenic Mechanism for HIV Infection? 141
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 141
LiHlm-Web: a web-application in order to collect, share and analyze immunological data of HIV patients in multicentric studies 140
Is it time to re-think the use of etravirine in patients with available genotypic resistance test? 140
Totale 17.354
Salva come PNG Salva come JPEG
Categoria #
all - tutte 157.168
article - articoli 145.749
book - libri 102
conference - conferenze 7.694
curatela - curatele 654
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.969
Totale 314.336
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021271 0 0 0 0 0 0 0 0 0 0 0 271
2021/20223.461 134 151 124 378 133 278 192 798 342 380 132 419
2022/20233.611 359 324 37 351 465 482 80 250 555 179 456 73
2023/20242.314 116 220 51 293 187 350 160 141 119 79 220 378
2024/20257.370 166 543 186 448 1.010 795 841 1.137 292 384 676 892
2025/202613.556 1.513 374 941 878 1.704 1.138 2.102 724 1.042 1.501 1.205 434
Totale 43.791